CERO vs. FLGC, SYBX, MRKR, NXTC, AYTU, CLDI, BCTX, CLRB, BGXX, and BCDA
Should you be buying CERo Therapeutics stock or one of its competitors? The main competitors of CERo Therapeutics include Flora Growth (FLGC), Synlogic (SYBX), Marker Therapeutics (MRKR), NextCure (NXTC), Aytu BioPharma (AYTU), Calidi Biotherapeutics (CLDI), BriaCell Therapeutics (BCTX), Cellectar Biosciences (CLRB), Bright Green (BGXX), and BioCardia (BCDA). These companies are all part of the "pharmaceutical products" industry.
CERo Therapeutics vs.
Flora Growth (NASDAQ:FLGC) and CERo Therapeutics (NASDAQ:CERO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability, valuation and community ranking.
Flora Growth has a beta of 2.01, indicating that its stock price is 101% more volatile than the S&P 500. Comparatively, CERo Therapeutics has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500.
CERo Therapeutics has lower revenue, but higher earnings than Flora Growth.
CERo Therapeutics has a net margin of 0.00% compared to Flora Growth's net margin of -30.99%. CERo Therapeutics' return on equity of 0.00% beat Flora Growth's return on equity.
36.0% of Flora Growth shares are owned by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are owned by institutional investors. 12.6% of Flora Growth shares are owned by company insiders. Comparatively, 12.7% of CERo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Flora Growth received 12 more outperform votes than CERo Therapeutics when rated by MarketBeat users. However, 75.00% of users gave CERo Therapeutics an outperform vote while only 60.00% of users gave Flora Growth an outperform vote.
Flora Growth currently has a consensus price target of $4.00, suggesting a potential upside of 521.12%. CERo Therapeutics has a consensus price target of $7.00, suggesting a potential upside of 1,256.59%. Given CERo Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe CERo Therapeutics is more favorable than Flora Growth.
In the previous week, CERo Therapeutics had 1 more articles in the media than Flora Growth. MarketBeat recorded 5 mentions for CERo Therapeutics and 4 mentions for Flora Growth. CERo Therapeutics' average media sentiment score of 0.48 beat Flora Growth's score of -0.59 indicating that CERo Therapeutics is being referred to more favorably in the news media.
Summary
CERo Therapeutics beats Flora Growth on 11 of the 16 factors compared between the two stocks.
Get CERo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CERO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CERo Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CERO) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy CERO Stock Free CERO Stock Alerts